Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in moderate to severe acute traumatic brain injury
IRCT20140915019185N3Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylphenidate in traumatic brain injury (TBI) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Level of consciousness and Hospital length of stay. Started Sep 2020; status: completed.
02
Drugs
methylphenidate
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20140915019185N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140915019185N3.